$0.00
−50.00%Price chart
Jul 10Jul 17Jul 24Jul 29Aug 3Aug 6Aug 12Aug 17
Key dataAug 17, 2026
Open$0.02
From 52W high−97.99%
Volume146059.00
Market cap$615.87
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataAug 17, 2026
Open
$0.02
From 52W high
−97.99%
Volume
146059.00
Market cap
$615.87
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
31.3
MomentumView details →
1D Return
−50.00%
YTD Return
−97.51%
SummaryUpdated Jun 1, 2026
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in August 2021 and focuses on developing pharmaceutical treatments for medical and aesthetic dermatological conditions. As a clinical-stage biotech firm, Dermata has no commercial products yet and is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound targeting common skin conditions like acne, psoriasis, and rosacea.
Similar companies
Latest newsMore news →
Dermata Therapeutics announced positive topline results from a cosmetic study of Tome Foundational Treatment, reporting improvements in skin appearance after four weekly treatments and overall skin improvement in more than 71% of participants after one treatment.5d agoDermata Therapeutics announced the commercial launch of its Tome Foundational Treatment skincare product, now available for purchase on its website.56d agoDermata Therapeutics announced the launch date of its first commercial product, Tome Foundational Treatment, expected on August 25, 2026.69d ago